A practical reference on 内脏脂肪: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-22. Anything still debated is marked as such rather than presented as settled.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
== Medical uses == Secukinumab is used to treat psoriasis, ankylosing spondylitis, psoriatic arthritis, and hidradenitis suppurativa. It is given by subcutaneous injection and is sold in a pre-filled syringe or autoinjector that can be used at home and as a lyophilized powder for use in hospitals and clinics. In October 2023, the FDA approved an intravenous variant of secukinumab. Secukinumab was not tested in pregnant women; animal studies did not show harm at relevant doses. The US Food and Drug Administration advises that the drug should be used in pregnant women only if the risk to the fetus is justified by the potential benefit; the European Medicines Agency (EMA) advises that women should not become pregnant while taking it. In the European Union, secukinumab is indicated for the treatment of:
Following this failure, a larger-scale version of the State Wula Agency was attempted in 1938 with the creation of the state-owned Xikang Animal Transport Company. This too had dismal results, as according to Liu (writing in a 1940 article), animals died en masse because Han colonists did not know how to take care of them and Kham herders had no incentive to do so. Once again, corruption was an issue, and the company was dissolved within a year after spending over 100,000 yuan. Despite this level of spending, it also suffered from a lack of veterinary medicine. A major debate over the wula system began after the collapse of both initiatives. One faction, led by Ren Zhuo, continued to call for abolishing the system to make way for state enterprise, Liu Wenhui, however, argued that the system would have to be kept and regulated due to the prior failures, and because it was the only major means of transportation in Kham. Another faction including Jiang Junzhang and the Frontier Administration Planning Commission argued for giving indigenous herders and other local voices more ownership and roles in company activities. There was a major ethnic dimension within this debate, because the anti-wula faction targeted the Kham herdsmen for their "obstinate" behavior and their control over the transport system.
== Risks and complications == The overall risk of Mohs micrographic surgery complications is very low. Reported adverse event rates are between 0.7% and 2.6% according to large multi-center prospective studies. Infection of the surgical site, hematoma formation, bleeding, and suboptimal wound repair with dehiscence or ischemic necrosis are the most reported adverse events. Complication rates leading to permanent damage or requiring hospitalization are below 0.1% and no deaths have resulted from this procedure. Certain patient factors may make complications more likely. These include immunosuppression (after an organ transplant) and use of anticoagulants or anti-platelets (“blood thinners”). Increased risk is not independently associated with older age. There are surgical characteristics which also may increase the risk of complications including cancer location (extremities vs. forehead), large tumors with depth, and tumors requiring advanced flap or graft repairs.
By coupling a market economy with political democracy, welfare provision, and social justice, Western European states offered East Europeans a model that, after 1989, they actively sought to emulate by joining NATO and the European Union rather than pursuing an American or reformed-Communist alternative.
Sources: en.wikipedia.org
=== Urinary tract infection === People with diabetes show an increased rate of urinary tract infection. The reason is that bladder dysfunction is more common in people with diabetes than in people without diabetes due to diabetes nephropathy. When present, nephropathy can cause a decrease in bladder sensation, which in turn can cause increased residual urine, a risk factor for urinary tract infections.
In 1771, Samuel Engel mentions, in his Traité de la nature, de la culture, et de l'utilité des pommes de terre par un ami des hommes, that half of Europeans live on bread and the other half on potatoes, and also that bread is made by mixing a third or a quarter of potato with cereal flour, which gives a dish "preferred by taste, to bread of pure wheat". He refers to various authors, including François Mustel who wrote Mémoire sur les pommes de terre et sur le pain économique. Mustel invented, before 1766, a kind of inverted jointer plane to grate potatoes, peeled or not, into a fine mush that must be mixed with wheat flour: the proportion of one 1/3 flour to 2/3 potatoes gives an edible bread he says, 50% of each ingredient a good one, and at the rate of 2/3 to 1/3, it is difficult to notice that the bread is not pure wheat; the mixture must be kneaded with ordinary sourdough, but less water is used and less heat is applied, which produces an additional saving; this bread keeps fresher for longer, it remains edible for fifteen days, instead of six for traditional bread. This prolongation of freshness, which is very appreciable, encourages many Ardennes farmers to add to their bread, until the 1980s, some 10% of potatoes, the Gaumais going up to 50%. Research on the use of the tuber for bread making was numerous in France at the end of the 18th century, but this did not lead to the massive perpetuation of this practice.
Chloramphenicol is an antibiotic useful for the treatment of a number of bacterial infections. This includes use as an eye ointment to treat conjunctivitis. By mouth or by injection into a vein, it is used to treat meningitis, plague, cholera, and typhoid fever. Its use by mouth or by injection is only recommended when safer antibiotics cannot be used. Monitoring both blood levels of the medication and blood cell levels every two days is recommended during treatment. Common side effects include bone marrow suppression, nausea, and diarrhea. The bone marrow suppression may result in death. To reduce the risk of side effects treatment duration should be as short as possible. People with liver or kidney problems may need lower doses. In young infants, a condition known as gray baby syndrome may occur which results in a swollen stomach and low blood pressure. Its use near the end of pregnancy and during breastfeeding is typically not recommended. Chloramphenicol is a broad-spectrum antibiotic that typically stops bacterial growth by stopping the production of proteins. Chloramphenicol was discovered after being isolated from Streptomyces venezuelae in 1947. Its chemical structure was identified and it was first synthesized in 1949. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.
=== 19S regulatory particle === The 19S particle in eukaryotes consists of 19 individual proteins and is divisible into two subassemblies, a 9-subunit base that binds directly to the α ring of the 20S core particle, and a 10-subunit lid. Six of the nine base proteins are ATPase subunits from the AAA Family, and an evolutionary homolog of these ATPases exists in archaea, called PAN (proteasome-activating nucleotidase). The association of the 19S and 20S particles requires the binding of ATP to the 19S ATPase subunits, and ATP hydrolysis is required for the assembled complex to degrade folded and ubiquitinated proteins. Note that only the step of substrate unfolding requires energy from ATP hydrolysis, while ATP-binding alone can support all the other steps required for protein degradation (e.g., complex assembly, gate opening, translocation, and proteolysis). In fact, ATP binding to the ATPases by itself supports the rapid degradation of unfolded proteins. However, while ATP hydrolysis is required for unfolding only, it is not yet clear whether this energy may be used in the coupling of some of these steps.
hydrogen bond A form of electrostatic interaction between an electronegative atom and a hydrogen atom bound to a second electronegative atom. Hydrogen bonding is unique because the small size of the hydrogen atoms permits proximity of the interacting electrical charges, and may occur as an intermolecular or intramolecular force.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.